Your session is about to expire
← Back to Search
N/A
Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response
Phase 2
Waitlist Available
Led By Armando Giuliano, MD, FACS, FRCSEd
Research Sponsored by Armando Giuliano
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at time of consent. assessed up to 3 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is studying if women with HER2+ breast cancer who have no remaining cancer after surgery can safely skip radiation treatment.
Eligible Conditions
- HER2-positive Breast Cancer
- Breast Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at time of consent. assessed up to 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at time of consent. assessed up to 3 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Feasibility of enrolling patients measured by proportion of recruited patients to participate in the trial
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Omit breast radiationExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Armando GiulianoLead Sponsor
Armando Giuliano, MD, FACS, FRCSEdPrincipal InvestigatorCedars-Sinai Medical Center
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are currently breastfeeding.You are a woman.You have already received radiation therapy as part of your previous treatment.You have been diagnosed with inflammatory breast cancer.You have had breast cancer before, whether it was invasive or non-invasive.
Research Study Groups:
This trial has the following groups:- Group 1: Omit breast radiation
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.